South Africa at the Frontline of HIV Prevention: Lenacapavir and Beyond

South Africa, home to the world’s largest HIV epidemic, is once again making headlines in global health research. This time, the focus is on lenacapavir, a groundbreaking long-acting injectable antiretroviral drug currently being tested in human trials across the country. Unlike daily pills or monthly injections, lenacapavir is administered just twice a year. Each dose provides six months of protection by targeting the HIV capsid, the protein shell that protects the virus’s genetic material. By binding to the capsid, lenacapavir disrupts multiple stages of HIV’s lifecycle — replication, assembly, and transport — making it far harder for the virus to adapt or develop resistance.

Researchers involved in the Cape Town trial note that lenacapavir could transform HIV prevention strategies. They highlight that adherence to daily medication remains a challenge for many South Africans, particularly young women. Simplifying prevention to two injections a year could significantly improve uptake and reduce new infections.

The trials are not happening in isolation. South African research centers are also participating in broadly neutralizing antibody (bNAb) studies, which explore whether combinations of antibodies can block HIV infection. Meanwhile, the BRILLIANT 011 Trial, launched in 2023, continues to test a novel vaccine candidate designed specifically for HIV subtype C, the strain most common in Southern Africa. Community activists stress that science alone is not enough. “We need equitable access,” says Thandiwe Nkosi, an HIV advocate in Durban. “If lenacapavir works, it must reach rural clinics, not just urban hospitals.”

President Ramaphosa and Motsoaledi on Lenacapavir

President Cyril Ramaphosa briefly mentioned the rollout of lenacapavir during his recent State of the Nation Address (SONA), signaling its importance at the highest level of government. Health Minister Aaron Motsoaledi has gone further, describing lenacapavir as “a game changer for South Africa”. He emphasized that the drug’s long-acting protection could revolutionize prevention efforts and ease the burden on the health system.

Motsoaledi explained that simplifying treatment and prevention is critical for communities where adherence to daily medication is difficult. He noted that lenacapavir’s twice-yearly dosing schedule could dramatically improve outcomes and reduce the risk of drug resistance. His remarks reflect growing optimism that South Africa can lead in adopting innovative HIV prevention strategies.

Conclusion

With lenacapavir poised for rollout in March–April 2026, South Africa is once again proving that it is not just a site of trials, but a leader in shaping the future of HIV prevention worldwide. The combination of cutting-edge research, government endorsement, and community advocacy underscores the country’s determination to confront HIV with new tools. While challenges remain in ensuring equitable access and building sustainable local pharmaceutical capacity, the recognition of lenacapavir as a “game changer” by Health Minister Motsoaledi and its mention in President Ramaphosa’s SONA speech highlight the momentum behind this innovation. For South Africa, resilience will mean turning scientific breakthroughs into widespread, practical solutions that protect its people.

Source: Lenacapavir: A Game Changer for HIV Prevention in South Africa – The Mercury / Cape Argus

⬅ Return to Home